Neoantigen landscape dynamics during human melanoma–T cell interactions
Els M.E. Verdegaal(Leiden University Medical Center), Sjoerd H. van der Burg(Leiden University Medical Center), Marit M. van Buuren(The Netherlands Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center), Caroline E. van der Minne(Leiden University Medical Center), Ellen Kapiteijn(Leiden University Medical Center), Sine Reker Hadrup(Herlev Hospital), Rikke Andersen(Herlev Hospital), Tom J. Harryvan(Leiden University Medical Center), Noel F.C.C. de Miranda(Leiden University), Marten Visser(Leiden University Medical Center), Ton N. Schumacher(Leiden University Medical Center), Hergen Spits(Erasmus MC Cancer Institute), Remko Schotte(AIMM Therapeutics (Netherlands))
Cited by 462
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k